Quanterix Corporation (QTRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 20.83%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 12.14%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 20.83% | Research and development expense / revenue. Period ending 2026-06-30. $31.95M ÷ $153.41M × 100 ≈ 20.83% |
| Stock-based compensation / revenue · 12 months | 12.14% | Share-based compensation / revenue. Period ending 2026-06-30. $18.62M ÷ $153.41M × 100 ≈ 12.14% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 31.95M USD | Research and Development Expense |
| Revenue | 153.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 18.62M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -152.87M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $31.95M | $153.41M | $18.62M | $-152.87M | (m) | 20.83% | 12.14% | (m) | (m) |
| 2026-03-31 | $33.21M | $144.98M | $19.78M | $-140.54M | (m) | 22.91% | 13.65% | (m) | (m) |
| 2025-12-31 | $35.92M | $138.90M | $20.72M | $-125.54M | (m) | 25.86% | 14.92% | (m) | (m) |
| 2025-09-30 | $35.19M | $130.20M | $21.14M | $-115.56M | (m) | 27.03% | 16.24% | (m) | (m) |
| 2025-06-30 | $35.29M | $125.78M | $20.33M | $-89.98M | (m) | 28.05% | 16.16% | (m) | (m) |
| 2025-03-31 | $34.38M | $135.69M | $20.18M | $-63.83M | (m) | 25.33% | 14.88% | (m) | (m) |
| 2024-12-31 | $31.08M | $137.42M | $19.99M | $-52.62M | (m) | 22.62% | 14.54% | (m) | (m) |
| 2024-09-30 | $30.23M | $133.81M | $19.48M | $-51.46M | (m) | 22.59% | 14.56% | (m) | (m) |
| 2024-06-30 | $28.97M | $129.33M | $19.16M | $-57.79M | (m) | 22.40% | 14.82% | (m) | (m) |
| 2024-03-31 | $26.81M | $125.98M | $18.13M | $-54.25M | (m) | 21.28% | 14.39% | (m) | (m) |
| 2023-12-31 | $24.86M | $122.37M | $16.76M | $-49.70M | (m) | 20.31% | 13.70% | (m) | (m) |
| 2023-09-30 | $23.47M | $116.64M | $16.10M | $-54.71M | (m) | 20.12% | 13.80% | (m) | (m) |
| 2023-06-30 | $22.90M | $111.95M | $14.52M | $-77.54M | (m) | 20.45% | 12.97% | (m) | (m) |
| 2023-03-31 | $23.58M | $104.43M | $15.52M | $-92.94M | (m) | 22.58% | 14.86% | (m) | (m) |
| 2022-12-31 | $25.89M | $105.52M | $15.44M | $-101.70M | (m) | 24.54% | 14.63% | (m) | (m) |
| 2022-09-30 | $28.02M | $109.98M | $16.71M | $-99.64M | (m) | 25.48% | 15.19% | (m) | (m) |
| 2022-06-30 | $28.20M | $111.03M | $17.95M | $-78.28M | (m) | 25.40% | 16.17% | (m) | (m) |
| 2022-03-31 | $28.33M | $112.90M | $16.42M | $-66.98M | (m) | 25.09% | 14.54% | (m) | (m) |
| 2021-12-31 | $27.98M | $110.56M | $15.97M | $-58.59M | (m) | 25.31% | 14.45% | (m) | (m) |
| 2021-09-30 | $26.46M | $106.40M | $14.17M | $-48.62M | (m) | 24.87% | 13.32% | (m) | (m) |
| 2021-06-30 | $25.03M | $110.10M | $12.53M | $-31.11M | (m) | 22.73% | 11.38% | (m) | (m) |
| 2021-03-31 | $22.59M | $97.86M | $11.38M | $-29.64M | (m) | 23.08% | 11.62% | (m) | (m) |
| 2020-12-31 | $20.17M | $86.38M | $10.10M | $-31.58M | (m) | 23.36% | 11.69% | (m) | (m) |
| 2020-09-30 | $18.36M | $76.16M | $8.64M | $-33.13M | (m) | 24.10% | 11.35% | (m) | (m) |
| 2020-06-30 | $16.90M | $59.72M | $8.11M | $-45.66M | (m) | 28.30% | 13.59% | (m) | (m) |
| 2020-03-31 | $16.61M | $60.12M | $7.21M | $-43.97M | (m) | 27.62% | 12.00% | (m) | (m) |
| 2019-12-31 | $16.19M | $56.73M | $6.39M | $-41.60M | (m) | 28.54% | 11.26% | (m) | (m) |
| 2019-09-30 | $15.84M | $51.69M | $6.20M | $-39.53M | (m) | 30.64% | 12.00% | (m) | (m) |
| 2019-06-30 | $16.32M | $47.34M | $6.24M | $-36.95M | (m) | 34.48% | 13.19% | (m) | (m) |
| 2019-03-31 | $16.01M | $42.45M | $5.53M | $-33.74M | (m) | 37.72% | 13.03% | (m) | (m) |
| 2018-12-31 | $15.80M | $37.63M | $4.88M | $-31.55M | (m) | 42.00% | 12.98% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $16.30M | $22.87M | $2.17M | $-26.00M | (m) | 71.28% | 9.48% | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $16.99M | $17.59M | $928.00K | $-21.71M | (m) | 96.63% | 5.28% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |